BELLUS Health Inc logo

BELLUS Health Inc (BLU)

Market Closed
28 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
NASDAQ (NGS) NASDAQ (NGS) Primary
$
14. 74
+0
+0.0339%
$
1.87B Market Cap
- P/E Ratio
- Div Yield
2.84M Volume
- Eps
$ 14.74
Previous Close
Add Transaction
Day Range
14.74 14.75
Year Range
6.38 14.76
Want to track BLU and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

BLU closed Wednesday higher at $14.74, an increase of 0.0339% from Tuesday's close, completing a monthly increase of 0% or $14.74. Over the past 12 months, BLU stock gained 0%.
BLU pays dividends to its shareholders, with the most recent payment made on Mar 22, 2011. The next estimated payment will be in 22 Jun 2011 on Jun 22, 2011 for a total of $0.0159.
BELLUS Health Inc has completed 2 stock splits, with the recent split occurring on Aug 19, 2019.
The company's stock is traded on one exchange.

BLU Chart

No Data

People also search for

TYRA
Tyra Biosciences, Inc.
$ 32.13
+1.645%
STOK
Stoke Therapeutics Inc.
$ 29.05
-0.2061%
MBX
MBX Biosciences, Inc.
$ 62.92
+7.8875%
SRPT
Sarepta Therapeutics Inc.
$ 17.22
-0.058%
WGS
GeneDx Holdings Corp.
$ 63.48
+2.9016%

BELLUS Health Inc (BLU) FAQ

What is the stock price today?

The current price is $14.74.

On which exchange is it traded?

BELLUS Health Inc is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is BLU.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 1.87B.

Has BELLUS Health Inc ever had a stock split?

BELLUS Health Inc had 2 splits and the recent split was on Aug 19, 2019.

BELLUS Health Inc Profile

Biotechnology Industry
Healthcare Sector
Roberto Francesco Bellini CEO
NASDAQ (NGS) Exchange
07987C204 CUSIP
CA Country
74 Employees
11 Mar 2011 Last Dividend
19 Aug 2019 Last Split
- IPO Date

Overview

BELLUS Health Inc. is a clinical-stage biopharmaceutical company based in Laval, Canada. Established in 1993, the company is dedicated to developing innovative therapeutic solutions aimed at addressing refractory chronic cough (RCC) and other conditions associated with cough hypersensitivity. With a focused mission, BELLUS Health is committed to advancing its research and clinical development capabilities to bring effective treatments to patients suffering from these challenging ailments.

Products and Services

  • BLU-5937

    BLU-5937 is the leading product candidate developed by BELLUS Health. It is a novel antagonist specifically designed to block the P2X3 receptor, which is believed to play a crucial role in the sensation of cough and related hypersensitivity. Currently, BLU-5937 is undergoing Phase II clinical trials targeting both refractory chronic cough and chronic pruritus, holding promise for patients who have limited treatment options.

Contact Information

Address: 275 Armand-Frappier Boulevard
Phone: 14506804500
Download app banner
Blog Affiliate Program About Terms Privacy Help Contact Us
2026 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark